Programmed death-1 (PD-1, PDCD1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4, CTLA4) play central roles in immune checkpoint pathways. Single nucleotide polymorphisms (SNPs) of PDCD1 and CTLA4 have been reported to be associated with susceptibility to some autoimmune diseases. However, the potential association between SNPs in these immune checkpoint genes and risk of chronic immune thrombocytopenia (cITP) remain controversial and obscure. The aims of this study were to clarify the influence of PDCD1 and CTLA4 SNPs on the risk of developing cITP and its clinical features. We obtained genomic DNA from 119 patients with cITP and 223 healthy controls; their genotypes were determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Patients with cITP had a significantly higher frequency of the PDCD1 +7209 TT genotype compared with healthy controls. The CTLA4 À1577 GG genotype and CT60 GG genotype showed higher frequencies of platelet count <5 9 10 9 /l at diagnosis, minimum platelet count <5 9 10 9 /l, and bleeding symptoms. Moreover, the PDCD1 À606 AA genotype and +63379 TT genotype were significantly associated with a lower number of patients who achieved a complete response to prednisolone treatment. Our results suggest that the immune checkpoint polymorphisms may affect the susceptibility to the clinical features of cITP, and treatment response of the affected patients.
Chronic immune thrombocytopenia (cITP) is an acquired immune-mediated disorder characterized by isolated thrombocytopenia. Several immune mechanisms contribute to the pathogenesis of cITP, including increased platelet destruction in the reticuloendothelial system and disturbed platelet production in the bone marrow (Chang et al, 2003) . The involvement of T cells has been known in the pathogenesis of cITP for many years. T helper (Th) type 1 (Th1) polarization occurs in cITP patients (Ogawara et al, 2003; Stasi et al, 2007) . Moreover, immune regulation is impaired in cITP patients. Some researchers have reported that regulatory T cell (Treg) function is decreased in patients with cITP (Stasi et al, 2008; Bao et al, 2010) .
Immune checkpoint pathways are critical modulators of the immune system, allowing the initiation of the immune response and preventing the onset of autoimmunity. Programmed death-1 (PD-1, also termed PDCD1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4, CTLA4) play central roles in immune checkpoint pathways. PD-1 is expressed on activated T cells and has been reported to suppress activation and cytokine production of lymphocytes by interacting with its ligands, PD-1 ligand-1 (PD-L1, CD274) and PD-1 ligand-2 (PD-L2, PDCD1LG2) (Dong et al, 1999; Freeman et al, 2000) . A crucial role of PD-1 for immune tolerance was demonstrated by a study where PD-1 deficient mice developed a spontaneous autoimmune disease (Nishimura et al, 1999) . CTLA-4 is homologous to CD28 and a competitive antagonist for B7 (CD80 and CD86) on the surface of antigen-presenting cells. CTLA-4 has greater affinity for B7 than CD28 and is responsible for T cell inactivation (Krummel & Allison, 1995; Collins et al, 2002) . CTLA-4 deficient mice rapidly develop lymphoproliferative disease with multi-organ lymphocytic infiltration and tissue destruction and die by 3-4 weeks of age (Tivol et al, 1995) . Therefore, CTLA-4 has a role in preventing autoimmune diseases by regulating immune tolerance.
Some researchers have speculated that the expression of immune checkpoint molecules affects the pathogenesis of cITP. The serum soluble PD-1 (sPD-1) levels in patients with cITP, which lacks the transmembrane domain of full-length PD-1 (Nielsen et al, 2005) , was decreased compared to that of healthy controls (Atesoglu et al, 2016) . Patients with cITP had lower expression levels of PD-1 and PD-L1 in the peripheral blood mononuclear cells than did healthy controls, although CTLA-4 expression levels between patients with cITP and healthy individuals were not significantly different (Zhong et al, 2016) . On the other hand, the platelets from patients with cITP expressed high levels of B7-1 (CD80), implicating the role of B7/CD28 co-stimulation in the pathogenesis of cITP (Semple et al, 1996) . However, the association between the immune checkpoint pathway and the pathogenesis of cITP is still unclear.
The production of PD-1 and CTLA-4 is strongly influenced by genetic factors. Single-nucleotide polymorphisms (SNPs) of the genes encoding PD-1 and CTLA-4 (PDCD1 and CTLA4, respectively) are implicated in the pathogenesis of many autoimmune diseases (Barreto et al, 2004; Ni et al, 2007; Takahashi et al, 2013; Tang & Zhou, 2013) . However, to the best of our knowledge, no previous studies have examined the possible association between PDCD1 and CTLA4 SNPs and cITP. To explore the role of PD-1 and CTLA-4 in the pathogenesis of cITP, we investigated the impact of PDCD1 and CTLA4 SNPs on the susceptibility to and clinical features of cITP.
Materials and methods

Patient characteristics
A total of 119 patients with cITP and 223 healthy controls (originating from Japan) were enrolled in this study. cITP was diagnosed as isolated thrombocytopenia (platelet count <100 9 10 9 /l) in the absence of other causes or disorders that may be associated with thrombocytopenia according to the criteria of the ITP International Working Group (IWG) (Rodeghiero et al, 2009) . cITP was also diagnosed if the disease lasted longer than 12 months. Patients aged under 10 years at onset of the disease and those with pregnancyrelated thrombocytopenia were excluded from the study. 'Bleeding symptoms' was defined as the occurrence of purpura, gum bleeding, epistaxis, gastrointestinal haemorrhage, haematuria, gynaecological haemorrhage (spotting between periods or very heavy period) and intracranial haemorrhage. We defined the indication for receiving treatment as a platelet count <10 9 10 9 /l or the presence of severe bleeding symptoms, which included gastrointestinal haemorrhage, haematuria and intracranial haemorrhage. The response to prednisolone therapy and splenectomywas analysed in 52 patients, excluding those who received treatments to eradicate the Helicobacter pylori. The response was defined according to the criteria of the ITP IWG (Rodeghiero et al, 2009) . A complete response (CR) was defined as a platelet count of ≥100 9 10 9 /l, whereas response (R) was defined as any platelet count between 30 and 100 9 10 9 /l and at least doubling of the baseline count. No response was defined as a platelet count <30 9 10 9 /l or less than doubling of the baseline count. This study was approved by the Institutional Review Board of Gunma University Hospital (approval #160007).
PDCD1 and CTLA4 genotyping
To detect PDCD1 SNPs (À606 G/A, +7209 C/T, +63379 C/T) and CTLA4 SNPs (À1722 A/G, À1577 A/G, +49 A/ G, CT60 A/G), we used the polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) method. Genomic DNA was isolated from whole blood using a DNA extraction kit (Qiagen GmbH, Hilden, Germany). For analysing the PDCD1 variants, the following primers were used:
CTLA4 variants were analysed using the following primers:
The PCR products were digested with the restriction enzyme NciI (for PDCD1 À606 G/A), BstUI (for PDCD1 +7209 C/ T), DrdI (for PDCD1 +63379 C/T), ApeKI (for CTLA4 À1722 A/G), HpyAV (for CTLA4 À1577 A/G), BbvI (for CTLA4 +49 A/G) and HpyCH4 (for CTLA4 CT60 A/G). The products were analysed by electrophoresis on 2% agarose gels. To confirm the accuracy of PCR-RFLP, the amplification products of several individuals were sequenced using an ABI Prism Genetic Analyser (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
All statistical analyses were performed with the IBM SPSS software package version 24 (IBM, Armonk, NY, USA). Genotype and allele frequencies of PDCD1 and CTLA4 were compared between the healthy controls and patients with cITP using the chi-square test. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated for each analysis. The clinical parameters of the cITP patients were compared with PDCD1 and CTLA4 polymorphisms using the nonparametric Mann-Whitney U test for continuous variables and the chi-square test for categorical variables. P < 0Á05 was considered statistically significant.
Results
Clinical characteristics of patients with cITP
The clinical characteristics of patients with cITP are shown in Table I . Eighty-seven of the 119 patients with cITP, were women (73Á1%) and 32 were men (26Á9%). Their median age at disease onset was 64Á0 years (range: 17Á4-86Á7 years).
The platelet count at initial diagnosis was <5 9 10 9 /l in 15 patients (12Á6%). The lowest platelet count during the course of this study was <5 9 10 9 /l in 23 patients (19Á3%).
Distribution of genotypes and allele frequencies among the healthy controls and patients with cITP
The distributions of genotype and allele frequencies of the selected are summarized in Table II . The cITP patients had a significantly higher frequency of the PDCD1 +7209 TT genotype compared with healthy controls (11Á8% vs. 4Á6%, OR = 2Á61, 95% CI = 1Á10-6Á20, P = 0Á025). However, no significant differences in the genotype frequencies of other PDCD1 (À606 G/A and +63379 C/T) and CTLA4 SNPs were observed between cITP patients and healthy controls. When we compared the distribution of each genotype according to sex and age among the control group and cITP patients as a whole, no significant differences were observed in the genotype or in the allele frequencies.
Association of PDCD1 polymorphisms with clinical variables of patients with cITP
The association of PDCD1 polymorphisms with the clinical variables of patients with cITP are summarized in Table III . Compared with the CC and CT genotypes, the PDCD1 +7209 TT genotype was significantly associated with a lower number of patients who received treatment for H. Pylori infection in particular [1 (7Á7%) vs. 39 (48Á7%), P = 0Á0057]. However, patients with the PDCD1 À606 G/A and +63379 C/TSNPs showed no significant differences in clinical variables.
Association of CTLA4 polymorphisms with clinical variables of patients with cITP
The association of CTLA4 polymorphisms with the clinical variables of cITP patients are summarised in Table IV. Patients with the CTLA4 À1577 GG genotype showed higher frequencies of platelet count <5 9 10 9 /l at diagnosis, minimum platelet count <5 9 10 9 /l and bleeding symptoms than those with the AA and AG genotypes [14 (19Á1%) vs. 2 (3Á9%), P = 0Á013; 18 (26Á5%) vs. 5 (9Á8%), P = 0Á023; and 49 (72Á1%) vs. 26 (51Á0%), P = 0Á018]. Moreover, the CTLA4 CT60 GG genotype was significantly associated with higher frequencies of patients with platelet count <5 9 10 9 /l at diagnosis, minimum platelet count <5 9 10 9 /l and bleeding symptoms compared to AA and AG genotype [13 (19Á7%) vs. 2 (3Á8%), P = 0Á0093; 17 (25Á8%) vs. 6 (11Á3%), P = 0Á047; and 53 (80Á3%) vs. 27 (50Á9%), P = 0Á014]. However, no significant differences in frequencies of patients with the CTLA4 À1722 A/G and +49 A/G SNPs were observed in clinical variables.
Association of PDCD1 and CTLA4 polymorphisms with the treatment response of cITP patients, excluding those who received treatment to eradicate H. pylori
We also explored the association between the seven polymorphisms and treatment response to prednisolone therapy and splenectomy in 52 patients with cITP, excluding those who received treatment to eradicate the H. pylori bacteria (Table V) . Patients with a PDCD1 À606 AA genotype were less likely to achieve a CR to prednisolone therapy than were those with the GG and GA genotypes [5 (38Á5%) vs. 28 Table I . Clinical characteristics of patients with chronic immune thrombocytopenia.
Number of patients (female/male) 119 (87/32) Age at disease onset (years), median (range) 64Á0 (17Á36-86Á7) Platelet count at diagnosis <5 9 10 9 /l, n (%) 15 (12Á6) Minimum platelet count <5 9 10 9 /l, n (%) 23 ( 
1Á00
Response to splenectomy 
Discussion
Both PDCD1 and CTLA4 are located on chromosome 2. Previous studies have shown that the SNPs in these genes influenced the expression of PD-1 or CTLA-4 (Fig 1; Anjos Ishizaki et al, 2010; Zheng et al, 2010; P erez-Garc ıa et al, 2013) . A luciferase assay of the human embryonic kidney 293 (HEK293) cells showed that the promoter activity of the PDCD1 À606A allele was lower than that of the PDCD1 À606G allele (Fig 1A; Ishizaki et al, 2010) . Using the same assay, Zheng et al (2010) showed that the PDCD1 +7209 C/T in the putative enhancer-like region created a negative -element in PDCD1 and that the PDCD1 +7209T allele had lower transcriptional activity of PD-1 in human T cells than the PDCD1 +7209C allele (Fig 1A) (Zheng et al, 2010) . The PDCD1 +63379 C/T results in the amino acid substitution from alanine (C allele) to valine (T allele) in exon 5 (A215V). Exon 5 in PDCD1 encodes the cytoplasmic domain of PD-1, including the immunoreceptor tyrosine-based inhibitory motif (ITIM) and the immunoreceptor tyrosine-switch motif (ITSM). The CTLA4 À1577 A/G alleles are located in promoter region. The CTLA4 CT60 A/G allele is located in the 3 0 -untranslated region of the CTLA4. In addition, activated human T cells containing the CTLA4 CT60 GG genotype had lower expression levels of soluble CTLA4 mRNA, a transcript variant that lacks the transmembrane domain (Fig 1B; P erez-Garc ıa et al, 2013). In this study, a higher frequency of the PDCD1 + 7209 TT genotype (low-expression type) was observed in patients with cITP. However, there were no significant differences in CTLA4 SNPs between cITP patients and healthy individuals. In a Turkish study, no significant link was observed between the CTLA4 +49 A/G polymorphism and susceptibility to cITP (Akt€ urk et al, 2010) . With regards to other diseases, the PDCD1 +7209 T allele (low-expression allele) was associated with a susceptibility to Kawasaki disease and systemic lupus erythematosus (Mostowska et al, 2008; Chun et al, 2010) . In addition, several reports have shown that melanoma patients develop cITP after anti-PD-1 monoclonal antibody therapy (Kanameishi et al, 2016; Shiuan et al, 2017) . Our results suggest that the genotype resulting in PD-1 low expression is implicated in the susceptibility to cITP in the Japanese population.
The CTLA4 À1577 GG and CTLA4 CT60 GG genotypes (low expression type) were significantly associated with higher frequency of bleeding symptoms and low platelet count (<5 9 10 9 /l) at diagnosis. CTLA4-Ig, which is a recombinant molecule combining the extracellular domain of CTLA-4 with a portion of the Fc domain of IgG1, prevented the induction of detectable alloantibodies and the division of a platelet-specific CD4+ T cell in mice that received a leucocyte-reduced platelet transfusion (Gilson et al, 2012) . Moreover, Guo et al (2016) showed that the CD28/CTLA-4 ratio of circulating T cells in patients with cITP was inversely correlated with the platelet count (Guo et al, 2016) . According to our results, the CTLA4 1577 GG genotype and CTLA4 CT60GG (low-expression) genotype might influence platelet destruction through CTLA-4 production. Thus, CTLA4 polymorphisms might contribute to the severity of cITP. According to these results, immune checkpoint polymorphisms may affect the clinical features of cITP.
To evaluate the association between PDCD1/CTLA4 SNPs and treatment response to prednisolone therapy and splenectomy, we excluded the patients who received treatment to eradicate H. pylori because the cases associated with H. pylori infection were classified as 'secondary ITP' according to the ITP IWG criteria (Rodeghiero et al, 2009 ). In addition, the symptoms were frequently resolved only by eradicating H. pylori in these patients. The PDCD1 À606 AA genotype (low-expression type) and PDCD1 +63379 TT genotype were significantly associated with a lower number of patients who achieved a CR to prednisolone therapy. This result suggested that PDCD1 polymorphisms were associated with the response to corticosteroid treatment.
Conclusion
Our study indicates that the PDCD1 +7209 C/T SNP is associated with a susceptibility to cITP. The CTLA4 À1577 A/G and CT60 A/G polymorphisms may affect the severity cITP. In addition, the PDCD1 À606 G/A and +63379 C/T polymorphisms may affect the patient's response to prednisolone treatment. To our knowledge, this is the first study showing the possible association between polymorphisms in immune checkpoint genes and pathogenesis of cITP. However, there are limitations in the interpretation of the results in this study because the sample size was relatively small with a total of 119 cITP patients. Therefore, further investigations with larger sample sizes are need to corroborate our results.
